Seeking Alpha

Baird says Dendreon's (DNDN -8.5%) Provenge may have a difficult road to commercial acceptance...

Baird says Dendreon's (DNDN -8.5%) Provenge may have a difficult road to commercial acceptance especially after this weekend's ASCO meeting in which both Bristol Myers (BMY flat) and Medivation (MDVN -2%) published impressive trial results for their prostate drugs. The firm loweres its 2014 and 2015 estimates for Provenge and said the drug may have trouble remaining relevant.
Comments (1)
  • shakazoid
    , contributor
    Comments (199) | Send Message
     
    Dr Cohen , where are you. Wanna see your usual +ve response and hope you have not sold out yet. :)
    4 Jun 2012, 04:37 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs